Research graph
References from Real-World Outcomes in the Evolving Second-Line Systemic Therapy Landscape in Hepatocellular Carcinoma. Local targets link to admitted publications; unresolved targets remain external evidence.
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2024 · External reference
Current epidemiology in hepatocellular carcinoma
10.1080/17474124.2021.1991792 · 2021 · External reference
Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival
10.1002/hep.1840160122 · 1992 · External reference
Natural history of minute hepatocellular carcinoma smaller than three centimeters complicating cirrhosis. A study in 22 patients
10.1016/0016-5085(86)90923-6 · 1986 · External reference
Comparison of outcomes of transplantation and resection in patients with early hepatocellular carcinoma: a meta-analysis
10.1111/j.1477-2574.2012.00500.x · 2012 · External reference
Natural history of hepatocellular carcinoma and prognosis in relation to treatment
1985 · External reference
Sorafenib in advanced hepatocellular carcinoma
10.1056/nejmoa0708857 · 2008 · External reference
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
10.1016/s0140-6736(18)30207-1 · 2018 · External reference
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
10.1056/nejmoa1915745 · 2020 · External reference
Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
10.1056/evidoa2100070 · 2022 · External reference
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
10.1016/s1470-2045(15)00050-9 · 2015 · External reference
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
10.1016/s1470-2045(18)30937-9 · 2019 · External reference
Efficacy, safety, and health-related quality of life (HRQoL) of regorafenib in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: Results of the international, double-blind phase 3 RESORCE trial
10.1093/annonc/mdw435.19 · 2016 · External reference
Cabozantinib in patients with advanced and progressing hepatocellular carcinoma
10.1056/nejmoa1717002 · 2018 · External reference
A Proportional hazards model for the subdistribution of a competing risk
10.1080/01621459.1999.10474144 · 1999 · External reference
A note on quantifying follow-up in studies of failure time
10.1016/0197-2456(96)00075-x · 1996 · External reference
Treatment patterns and survival outcomes among patients with hepatocellular carcinoma
10.1001/jamanetworkopen.2025.51665 · 2025 · External reference
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients
2023 · External reference
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
10.1097/hep.0000000000000466 · 2023 · External reference
Systemic therapy for advanced hepatocellular carcinoma: ASCO Guideline Update
10.1200/jco.23.02745 · 2024 · External reference
Salvage ipilimumab plus nivolumab after anti-PD-1/PD-L1 therapy in advanced hepatocellular carcinoma
10.1158/2767-9764.crc-23-0072 · 2023 · External reference
Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior immune checkpoint inhibitor-based combination therapies: a multicenter retrospective study
10.1007/s00432-022-04206-8 · 2023 · External reference
Comparative efficacy and safety of second-line therapies for patients with advanced hepatocellular carcinoma: a systematic review and network meta-analysis of randomized controlled trials
10.3389/fphar.2025.1697949 · 2025 · External reference
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
10.1016/s0140-6736(16)32453-9 · 2017 · External reference
NAFLD-driven HCC: safety and efficacy of current and emerging treatment options
10.1016/j.jhep.2021.09.007 · 2022 · External reference
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
10.1038/s41586-021-03362-0 · 2021 · External reference
Efficacy of systemic therapy for advanced hepatocellular carcinoma based on etiology: a systematic review and network meta-analysis of randomized phase III trials
10.1016/j.critrevonc.2025.104842 · 2025 · External reference
Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC
10.1016/j.jhep.2025.03.033 · 2025 · External reference
